Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
August 09, 2018
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights
MENLO PARK, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third…


August 02, 2018
Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018
MENLO PARK, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ: CORI) today announced that it will report financial results for the third quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. Corium will host a conference…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2